Renal and systemic hemodynamics were measured during titration of dopamine and serially after intravenous administration of enalaprilat in nine patients with chronic severe congestive heart failure. During titration of dopamine, renal blood flow increased by 99%, from 304 ± 120 to 604 ± 234 ml/min (p < .01) at a dose of dopamine of 2.1 gg/kg/min, which produced only a 21 % increase in cardiac index, from 1.96 ± 0.36 to 2.38 ± 0.35 liters/min/m2 (p < .05). Cardiac index was increased maximally at a dose of 4.0 ,ug/kg/min dopamine; however, renal blood flow was not further augmented. In contrast, after intravenous administration of enalaprilat, peak improvement of renal blood flow and cardiac index occurred concomitantly. Renal blood flow increased by 35%, from 316 ± 97 to 427 + 107 ml/min (p < .05), and cardiac index increased by 18%, from 1.99 ± 0.40 to 2.35 + 0.40 liters/min/m2 (p < .05). At similar increases in cardiac index, dopamine produced a greater increase in renal blood flow than enalaprilat: 604 ± 234 vs 427 + 107 ml/min (p < .05). Mean systemic arterial pressure, however, was greater with dopamine than with enalaprilat (78.1 ± 16.7 vs 70.2 ± 17.2 mm Hg; p < .05) at peak effect. Thus, although both drugs appear to be potent renal vasodilators in patients with severe congestive heart failure, dopamine may be more effective in augmenting renal blood flow. Circulation 72, No. 4, 846-852, 1985. IN PATIENTS with severe congestive heart failure, blood flow to the kidneys is reduced.' Although it is unclear whether this reduction in renal blood flow is proportionate to the fall in cardiac output,2' 3 drugs that increase cardiac performance as well as specifically dilate the renal vasculature are of particular interest in the treatment of this entity.
cardiac output and renal blood flow in patients with congestive heart failure and to compare these effects with those of intravenously administered enalaprilat, an angiotensin-converting enzyme inhibitor presently under investigation.
Methods
Patients. Eight men and one woman with severe congestive heart failure, consistent with functional class III or IV according to the New York Heart Association, were studied (average age 59 years, range 34 to 71). The etiology of heart failure was coronary artery disease in five patients and an idiopathic cardiomyopathy in four. Left ventricular ejection fraction was less than 20% in all patients. Eight patients were in sinus rhythm, and one patient was in atrial fibrillation. All were markedly limited in physical activity by fatigue and/or dyspnea, and the average maximum oxygen uptake during graded treadmill exercise was 11.5 + 2.0 ml/kglmin. No patient had sustained a myocardial infarction within 1 month of the study. Patients were on optimal and stable doses of furosemide and digoxin for 2 weeks, and the mean digoxin level immediately before the study was 1.2 ng/ml. Creatinine clearance, determined during a 24 hr urine collection the day before the study, averaged 72 ± 10.5 ml/min.
Patients were admitted to the coronary care unit and maintained on a 2 g/day sodium diet for at least 3 days before the study. Daily doses of digoxin and furosemide were maintained throughout the study and administered at night. The nature, potential benefits, and possible risks of the study were fully explained to the patients, who gave their written consent.
Hemodynamics. On the day of study, right heart catheterization was performed in all patients by means of a triple-lumen, flow-directed, balloon-tipped catheter (Edwards Laboratories). An intra-arterial catheter was inserted percutaneously into a radial artery for measurement of systemic arterial pressure. Systemic arterial, right atrial, pulmonary arterial, and pulmonary capillary wedge pressures were determined with Gould Statham P231D transducers and recorded on an Electronics for Medicine photographic recorder. Cardiac output was determined in triplicate (less than 10% variation) by the thermodiluton technique, with iced 5% dextrose and a bedside computer (Model 9250A). Heart rate was recorded continuously from two bedside electrocardiographic monitoring devices.
Renal blood flow was determined as the left renal venous blood flow by the continuous thermodilution technique9-11 with a No. 7F dual thermistor catheter (Webster Laboratories). The catheter is preformed with a curved terminal bend as previously described,'2' 13 to facilitate introduction and stable positioning in the renal vein. The injection orifice is located 15 mm proximal to the distal end and on the concavity of the bend to prevent vascular wall contact, with the opening obliquely oriented at 30 to 40 degrees against the blood stream to increase turbulence and to ensure optimal indicator/blood admixture. The external "dilution" thermistor is located 10 mm proximal to the injection orifice, and the second "indicator" thermistor is within the catheter just proximal to the orifice. The catheter was introduced into the femoral vein via the Seldinger technique and guided into the left renal vein under fluoroscopy. Optimal positioning within the renal vein and the absence of accessory veins were confirmed by injection of meglumine diatrizoate through the catheter. The position was confirmed by determination of the oxygen saturation of venous blood withdrawn from the catheter, which was greater than 85% in all cases. Determination of oxygen saturation of blood withdrawn from the catheter was repeated frequently during the study. At the end of the study, the position of the catheter was reconfirmed under fluoroscopy. For each determination of blood flow, room temperature 5% dextrose was infused through the catheter by a Harvard pump (Model 921) at a constant rate of 50 ml/min until the resistance deflections of both thermistors consequent to the thermal dilution temperature changes were stable. Each renal blood flow was measured at least five times, and three measurements within 10% were averaged. A standard three-channel thermodilution Wheatstone Bridge (Webster Laboratories) was used to convert the resistance changes into calibrated voltages, which were recorded on photographic paper. Blood flow was then calculated from the formula derived by Ganz et al.9: FB = F, X 1.08 (ATI/ATB) -1 where F = flow (ml/min); B = blood; I = indicator; T = temperature ('C). A previously validated modification of this formula, derived to correct for thermotransport within the Webster catheter at blood flow rates ranging from 300 to 1500 ml/min,14 was used:
FB-COrr = (FB-UnCOrr X 1.427) -130
Such correction was made in the calculation of renal blood flow in patients 1, 2, 3, 5, 7, and 8. The following parameters were determined: cardiac index (liters/min/m2) = cardiac output/body surface area; stroke volume index (ml/m2) = cardiac index x 1000/heart rate; systemic vascular resistance (dyne-sec-cm-5) 80 x (mean systemic arterial pressureright atrial pressure)/cardiac output; renal vascular resistance (dyne-sec-cm-5 X 103) = 80 (mean systemic arterial pressureright atrial pressure)/renal blood flow. Hemodynamic parameters were determined during the first control period before infusion of dopamine, at each dose (,ug/kg/min) during the dopamine titration, during the second control period before administration of enalaprilat by intravenous bolus, and thereafter at intervals of 30, 60, 90, and 120 min after the administration of enalaprilat.
Plasma renin activity. Blood samples were withdrawn for determinations of plasma renin activity in all patients during the control periods before infusion of dopamine and before administration of enalaprilat, at the dose rate resulting in peak augmentation of renal blood flow during infusion of dopamine, and at the time of maximum increase in renal blood flow after the intravenous bolus of enalaprilat. Before each control period, patients assumed the supine position for 30 to 60 min and remained supine during the dopamine titration and for 2 hr after administration of enalaprilat. Mixed venous blood was withdrawn from the indwelling thermodilution catheter into chilled collection tubes containing ethylenediaminetetraacetate. Specimens were immediately centrifuged and the plasma was removed and maintained at 4°C. Plasma renin activity (ng/ml/hr) was measured by radioimmunoassay of generated angiotensin I by use of a commercially available kit (Immutrope ER, Squibb & Sons, Princeton, NJ).
Drug administration Dopamine. After baseline determinations and while the patient was in the fasting state, dopamine was infused at an initial dose of 1 ug/kg/min and increased every 10 min by 1 gg/kg/min until a maximal cardiac output was reached or undesirable side effects were elicited. Adverse effects were defined as a 10% increase in heart rate or systolic arterial pressure above control values or as precipitation of recurrent episodes of nonsustained ventricular tachycardia. Measurements were repeated after 5 min at each rate of infusion.
Enalaprilat. Three hours after administration of dopamine and after return of systemic and renal hemodynamics to baseline values, enalaprilat was administered to all patients as a single intravenous bolus at a dose of 2.5 mg in four patients, 10 mg in three, and 5 mg in the remaining two. A dose-ranging study in these patients demonstrated similar peak hemodynamic responses to doses ranging from 2.5 to 10 mg. Measurements were repeated at 30, 60, 90, and 120 min after intravenous bolus of enalaprilat.
Statistical analysis. The results are expressed as mean ± SD and were considered significant at p < .05. Statistical significance for effects of titration of dopamine and duration of effects of enalaprilat are based on the results of analysis of variance techniques. Comparison of the systemic and renal hemodynamic effects of dopamine and enalaprilat were made using a twofactor repeated measures analysis of variance.
Results
Hemodynamic results. During infusion of dopamine at increasing rates, renal blood flow and cardiac index did not rise in parallel (figure 1). In eight of the nine patients, renal blood flow increased maximally at an infusion rate of 2 gg/kg/min, whereas in one patient this occurred at an infusion rate of 3 ,ug/kg/min. Thus, at an average infusion rate of 2.1 gug/kg/min, renal blood flow increased from 304 + 120 ml at control to a peak of 604 + 234 ml/min (p < .01), and cardiac from20.5 ± 5.4to 11.0 ± 2.9 dyne-sec-cm-5 x 103 (p < .05), respectively. A maximum increase in cardiac index was obtained in seven patients at a rate of infusion averaging 4 gg/kg/min (range 3 to 5). In the remaining two patients, ventricular arrhythmias limited the maximum rate of infusion to 4 ,ug/kg/min. Thus, at a mean infusion rate of 4.0 ,ug/kg/min, cardiac index increased further from 2.38 + 0.35 to a peak of 2.87 ± 0.46 liters/min/m2 (p < .05), whereas renal blood flow had not changed significantly, 604 + 234 vs 572 + 222 ml/min. The peak increase in cardiac index was accompanied by a further reduction in systemic vascular resistance from 1384 + 322 to 11 14 ± 271 dyne-seccm'5 (p < .01). Renal vascular resistance was unchanged, 11 .0 + 2.9 vs 11.6 ± 2.6 dyne-sec-cm-5 x 103. At maximum increase in cardiac index, the changes in mean systemic arterial and pulmonary capillary wedge pressures were not significant when compared with control values, 81.8 17 The ratio of renal blood flow to cardiac output increased from 18 ± 5% at control to a peak of 23 ± 7% (p < .05). Renal blood flow increased in every patient, notwithstanding reduction in mean systemic arterial pressure by as great as 20 mm Hg or to as low as 46 mm Hg. At 60 min after the intravenous bolus of enalaprilat, mean systemic arterial pressure, renal blood flow, and systemic vascular resistance were still significantly different from baseline values. The other parameters were not, although they had not returned to baseline values at 60 min.
Both dopamine and enalaprilat produced relatively greater increases in renal blood flow than cardiac index. However, with dopamine, the peak renal blood flow was significantly greater than that attained with enalaprilat, 604 ± 254 vs 427 ± 107 ml/min (p < .05), whereas the cardiac index values measured concomitantly were similar with both drugs, 2.38 ± 0.35 vs 2.35 ± 0.40 liters/min/m2 (figure 3). Mean systemic arterial pressure was significantly lower with enalaprilat than with dopamine, 70. was also lower but not significantly, 1235 ± 414 vs 1348 ± 324 dyne-sec-cm-5.
Plasma renin activity. After the intravenous bolus of enalaprilat, plasma renin activity measured at peak increase in renal blood flow rose from 3.5 ± 0.5 to 10. 6 1.1 ng/ml/hr (p < .05). During infusion of dopamine, plasma renin activity did not change significantly when compared with control values, 3.8 0.4 vs 3.5 ± 0.8 ng/ml/hr.
Discussion
In this study, renal blood flow was determined by local thermodilution technique during titration of dopamine and serially after intravenous administration of enalaprilat in patients with chronic severe congestive heart failure, with concomitant assessment of systemic hemodynamic parameters. During titration of dopamine, improvement of renal blood flow was greater than that achieved with enalaprilat and was found to peak at a low dose before maximal augmentation of cardiac performance. In contrast, peak increase in renal blood flow and cardiac output subsequent to administration of enalaprilat occurred concurrently.
In instrumented dogs, dopamine selectively increases renal blood flow predominantly by dilating the renal vasculature rather than by enhancing cardiac performance. 15 Similarly, Hollenberg et al.,11 using the xenon washout technique, demonstrated in normal subjects that renal blood flow was optimized by a dose of 3 gg/kg/min dopamine. In hypertensive patients, Breckenridge et al.'7 showed an improvement in the renal fraction of the cardiac output in response to dopamine in doses of 1 to 2 ,ug/kg/min. In patients with congestive heart failure, McDonald et al. 5 found an increase in renal blood flow at an average dose of 2.6 gg/kg/min dopamine (range 1.3 to 3.6).
Rosenblum et al.,18 using the para-aminohippurate clearance method, observed similar improvements in renal blood flow as well as the renal fraction of cardiac output in patients with heart failure in response to dopamine doses ranging in individuals from 2.1 to 5.8 ,ug/kg/min. However, the dose-response relationships for the renal and systemic hemodynamic effects of dopamine were not characterized in these two previous studies.
Indeed, the para-aminohippurate clearance method previously used to determine renal blood flow, did not provide for the instantaneous and repetitive measurements needed to establish a dose-response curve. 19 In contrast, measurement thermodilution technique is more appropriate for such an analysis by allowing temporal correlations with systemic hemodynamic parameters. In this study, the maximum increase in renal blood flow averaged 99% and was attained at a dopamine dose of 2.1 ,ug/kg/min, which produced only a 21% increase in cardiac output. Such selective improvement in renal perfusion is consistent with specific renal vasodilatation, mediated via stimulation of postsynaptic dopaminergic receptors. In addition, stimulation of presynaptic dopaminergic receptors with adrenergicinhibiting activity may have facilitated renal vasodilatation in patients with severe heart failure in whom heightened sympathetic activity contributes to elevated renal vascular resistance.20 At peak increase in cardiac output, which occurred at an average dopamine dose of 4 gg/kg/min, renal blood flow had not increased further. In fact, it had even decreased in some patients who experienced a concomitant increase in systemic arterial pressure. Indeed, with higher doses of dopamine, further improvement in renal blood flow may have been effectively countered by concurrent dopamine-mediated stimulation of renal vascular a-adrenergic receptors. In fact, studies by McNay et al. 1 have demonstrated that the renal vasoconstrictor ef-850 fects of dopamine can be completely eliminated in dogs by pretreatment with the a-adrenergic blocking agent phenoxybenzamine.
Intravenous administration of enalaprilat improved cardiac performance in all patients, whereas systemic arterial pressure and vascular resistance were significantly reduced. Renal blood flow was improved substantially by enalaprilat. However, in contrast to the response to dopamine, peak augmentation of renal blood flow and cardiac output were concurrent, thereby suggesting similar mechanisms for both systemic and regional circulatory effects. The selective improvement in renal blood flow observed after administration of enalaprilat is consistent with a major role of angiotensin II in mediating renal vasoconstriction and thereby reduced renal blood flow in patients with severe heart failure. The rise in plasma renin activity noted at peak hemodynamic effect attests to the inhibition of the angiotensin-converting enzyme by enalaprilat. Whether inhibition of bradykinin degradation or enhanced prostaglandin production also contribute to the systemic hemodynamic effects of enalaprilat is still unclear. Nonetheless, these mechanisms do not appear to be important mediators of renal vasodilatation.21
Our findings with enalaprilat were consistent with CIRCULATION ---L .p< 0.01-oL 3.0r L the short-term effects of the angiotensin-converting despite short-term improvement in systemic hemodyenzyme inhibitor captopril on renal hemodynamics re-namics, renal flow, determined by para-aminohippuported by Creager et al. 22 ; however, they differ from rate clearance, did not change during the first few days the experience of Powers et al.23 In the latter study, of therapy with captopril. Of importance, the reduction was more profound than that observed by other investi-gators4'22.24 and a significant correlation was present between changes in systemic arterial pressure and renal blood flow. In particular, renal blood flow decreased when mean systemic arterial pressure fell below 60 mm Hg, which may endanger renal autoregulation. 25 Differences in patient population, severity and chronicity of the disease, and sodium intake may also partially explain the disparate results.26 27 Although dopamine and enalaprilat increased cardiac output similarly, the improvement in renal blood flow was less marked with enalaprilat than with dopamine. Because renal perfusion pressure was lower during administration of enalaprilat, comparison of the direct renal vasodilator activity of the two drugs was not attempted. Nevertheless, because the increase in renal blood flow produced by dopamine is not associated with a fall in systemic arterial pressure, loss of renal autoregulation is unlikely to occur. In contrast, the renal response to angiotensin-converting enzyme inhibition may not always be beneficial, since renal autoregulation may be lost because of an excessive decrease in systemic arterial pressure. Accordingly, the development of new, orally active, dopamine-like agents, or the administration of oral levodopa,28 appears to be of great promise in the treatment of chronic congestive heart failure. However, although both dopamine and enalaprilat were shown to increase renal blood flow, the concomitant effects on renal glomerular filtration and urinary sodium excretion were not evaluated. Accordingly, further studies are needed to determine whether the improvement in renal blood flow observed with dopamine and enalaprilat is associated with changes in renal function.
